Mitochondrial dynamics and protective effects of a mitochondrial division inhibitor, Mdivi-1, in lipopolysaccharide-induced brain damage

Biochem Biophys Res Commun. 2018 Feb 12;496(3):865-871. doi: 10.1016/j.bbrc.2018.01.136. Epub 2018 Feb 1.

Abstract

Sepsis is one of the most common reasons for mortality in Intensive Care Units. As a common but severe neurological complication, sepsis associated encephalopathy (SAE) has always been ignored and there is no generally accepted treatment. In this study, we demonstrated that Mdivi-1 ameliorated brain damage assessed by Nissl staining. Furthermore, Mdivi-1 reduced TUNEL-positive cells in hippocampus, and inhibited S100 calcium binding protein B (S100B) and neuron-specific enolase (NSE) release into plasma. Biochemical analysis also showed that Mdivi-1 protected hippocampus from oxidative stresses. Western blot analysis revealed that Mdivi-1, as a Drp1 inhibitor, inhibited LPS induced dynamin-related GTPase (Drp1) increase. Interestingly, it can also attenuate LPS induced optic atrophy 1 (OPA1) and phosphorylated Drp1 (p-Drp1) decrease. Thus Mdivi-1 protected rats from SAE, and this protective effect could be associated with its inhibition of Drp1 and its activation of p-Drp1 and OPA1. Mitochondrial dynamics may be a potential pharmacological therapeutic target for treating SAE.

Keywords: Drp1; Mdivi-1; Mitochondrial dynamics; OPA1; Oxidative stress; Sepsis-associated encephalopathy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brain / drug effects
  • Brain / metabolism*
  • Brain / pathology*
  • Dose-Response Relationship, Drug
  • Dynamins / metabolism
  • Lipopolysaccharides
  • Male
  • Mitochondria / drug effects*
  • Mitochondria / metabolism*
  • Mitochondria / pathology
  • Neuroprotective Agents / administration & dosage
  • Quinazolinones / administration & dosage*
  • Rats
  • Rats, Sprague-Dawley
  • Sepsis-Associated Encephalopathy / drug therapy*
  • Sepsis-Associated Encephalopathy / metabolism
  • Sepsis-Associated Encephalopathy / pathology*
  • Treatment Outcome

Substances

  • 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone
  • Lipopolysaccharides
  • Neuroprotective Agents
  • Quinazolinones
  • Dnm1l protein, rat
  • Dynamins